TD Cowen Maintains Buy on Travere Therapeutics, Raises Price Target to $60
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
TD Cowen analyst Tyler Van Buren maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $45 to $60.
TD Cowen analyst Tyler Van Buren maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $45 to $60.